-

PhysIQ Expands Clinical Leadership Team, Dr. Steve Steinhubl Joins as Chief Medical Officer

CHICAGO--(BUSINESS WIRE)--Dr. Steve Steinhubl, a leader in reinventing medicine through the convergence of healthcare and technology and an expert in physiology, has joined physIQ as Chief Medical Officer. Dr. Steinhubl will help advance the adoption of physIQ’s artificial intelligence (AI)-based analytics for improved clinical outcomes and lower costs.

“Over the last 5 years I’ve been fortunate enough to collaborate with the physIQ team on a number of projects,” says Steinhubl. “Their unwavering commitment to evidence-driven research is unparalleled. PhysIQ’s vision and drive for using cutting-edge digital technologies to enable more precise and individualized healthcare makes me extremely proud to be joining their amazing team. I look forward to helping expand upon fundamental research into early detection of medical conditions that would help drive better outcomes.”

Dr. Steinhubl has been the Director of Digital Medicine at Scripps Research Translational Institute (SRTI) for over 7.5 years. He will continue at SRTI as he takes on this new position. In his role at physIQ, Steinhubl will help drive the deployment of physIQ’s unique AI-based analytics platform to health systems and provider groups worldwide.

“Continuous Remote Patient Monitoring is emerging as a must-have capability for innovative-thinking, high-value healthcare systems. The technology from physIQ provides the right solution to enable and, in fact, lead the ongoing transformation in care delivery, as well as success in reimbursement models that are increasingly tied to value. Over the past 4 years, I’ve had the pleasure of working with Steve in his advisory role and am thrilled that he is joining the physIQ executive team,” said Dr. Stephen Ondra, physIQ’s former CMO. Ondra will continue as a Senior Advisor for physIQ.

Prior to joining Scripps, Steve was the Director of Cardiovascular Wellness and the Medical Director for Employee Wellness for the Geisinger Healthcare System. He was Chief Cardiology Fellow at the Cleveland Clinic and served as Global Medical Vice President for The Medicines Company based in Zurich Switzerland. Steve has been principal investigator or helped lead over a dozen large-scale international randomized trials and has authored over 275 peer-reviewed manuscripts as well as numerous book chapters, and abstracts.

“As we continue an incredible growth and innovation period for physIQ, Steve will help us lead adoption and expansion of our solutions for healthcare delivery and digitally enabled clinical trials. He is a recognized thought leader and researcher of digital medicine solutions, their adoption and the value they provide,” said Gary Conkright, CEO of physIQ. “Steve has been a long-time advisor and friend of physIQ, and we are honored to have him onboard as we strengthen our leadership position in the industry.”

About physIQ

PhysIQ is the leader in digital medicine, dedicated to generating unprecedented health insight using continuous wearable biosensor data and advanced analytics. Its enterprise-ready cloud platform continuously collects and processes data from any wearable biosensor using a deep portfolio of FDA-cleared analytics. The company has published one of the most rigorous clinical studies to date in digital medicine and are pioneers in developing, validating, and achieving regulatory approval of Artificial Intelligence-based analytics. With applications in both healthcare and clinical trial support, physIQ is transforming continuous physiological data into insight for health systems, payers, and pharmaceutical companies.

For more information, please visit www.physIQ.com. Follow us on Twitter and LinkedIn.

Contacts

Media Contacts
Christa Carroll
Senior Vice President
Outlook Marketing Services
Ph: 630-408-9164
christa@outlookmarketingsrv.com

physIQ


Release Versions

Contacts

Media Contacts
Christa Carroll
Senior Vice President
Outlook Marketing Services
Ph: 630-408-9164
christa@outlookmarketingsrv.com

Social Media Profiles
More News From physIQ

physIQ’s eVO2Max™ demonstrates breakout ability to estimate cardiopulmonary functional capacity from wearable sensor data during daily routine activity

CHICAGO--(BUSINESS WIRE)--physIQ today announced a novel approach to estimating maximum oxygen utilization (VO2Max) using wearable biosensors and deep neural network technology. This innovative biomarker, eVO2Max, can be generated using 24 hours of continuous vital signs and activity data captured during routine daily activities. This enables remote assessment at higher frequency and convenience than by in-clinic tests of cardiopulmonary functional capacity, such as the gold standard, cardiopul...

Innovative Oncology CRO OncoBay Clinical Joins physIQ Intrepid Partner Program

CHICAGO & TAMPA, Fla.--(BUSINESS WIRE)--physIQ, a leader in continuous remote patient monitoring (cRPM) and data analytics, announced today that OncoBay Clinical, Inc., a leading oncology-focused Contract Research Organization (CRO), has joined the Intrepid™ Partner Program. OncoBay will use physIQ’s technology to monitor and evaluate the health and safety of cancer patients and treatment effectiveness in near real-time during the clinical trial process. The Intrepid™ Partner Program uniquely e...

physIQ Launches the Intrepid Partner Program

CHICAGO--(BUSINESS WIRE)--physIQ announced today the launch of its Intrepid™ Partner Program, designed to enable the Life Sciences solutions ecosystem to deliver next generation near real time patient insights powered by high-fidelity medical grade biosensor data streams in both clinical and remote patient settings. The physIQ Intrepid Partner Program will provide a distinct advantage to its members when competing for the business of both large and small life science companies alike. The unique...
Back to Newsroom